HISCO's three chemicals, polyprizine granules, enter the site for inspection

According to the website of the State Food and Drug Administration (CFDA) on June 23, the three digestive drugs of Hisilicon, polyprizine granules, will enter the site for inspection, which means that the drug only needs to pass the inspection links of production environment and production process, and is expected to be approved within the year Polyprizine granules are digestive drugs, the main component is polyprizine, used in the treatment of gastric ulcer This product is the only new type of gastric mucosa protective agent with multi-layer repair mechanism and long-term physical coverage, which can effectively reduce the recurrence rate of ulcer It is significantly superior to the traditional gastric mucosa protective agent in terms of safety, and is listed as one of the "top ten prescription drugs in China in 2012" Polyprizin is a new generation of anti gastric ulcer drug developed by hamari new drug industry Co., Ltd in Japan It is the first zinc containing compound for clinical use It passed the review of Japan's Ministry of health and health in 1994 In China, at present, only Jilin Boda Weiye Pharmaceutical Co., Ltd is a manufacturer of jupurui zinc granules Hisico is the leader in the field of parenteral nutrition medicine, characteristic anti infection medicine and hepatobiliary disease medicine In the prospectus, the company has said that it will focus on tracking the development trend of innovative generic drugs in the international mainstream market, and establish the domestic leading new drug variety reserve resources The approval of the production of polyprizin granules soon means that the company has another strong member in the field of digestive medicine.